A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis

20122,019 citationsJournal Articlebronze Open Access

Authors

Srđan Verstovšek · The University of Texas MD Anderson Cancer Center

Ruben A. Mesa · Mayo Clinic in Arizona

Jason Gotlib · Cancer Prevention Institute of California

Richard S. Levy · Incyte (United States)

Vikas Gupta · University of Toronto

John F. DiPersio · Washington University in St. Louis

John Catalano

Abstract

Ruxolitinib, as compared with placebo, provided significant clinical benefits in patients with myelofibrosis by reducing spleen size, ameliorating debilitating myelofibrosis-related symptoms, and improving overall survival. These benefits came at the cost of more frequent anemia and thrombocytopenia in the early part of the treatment period. (Funded by Incyte; COMFORT-I ClinicalTrials.gov number, NCT00952289.).

Topics & Keywords

Myeloproliferative Neoplasms: Diagnosis and Treatment Eosinophilic Disorders and Syndromes Kruppel-like factors research

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 366, Issue 9, pp. 799-807

DOI: 10.1056/nejmoa1110557

Field-Weighted Citation Impact: 84.80